scholarly journals GnRH Neurons of Young and Aged Female Rhesus Monkeys Co-Express GPER but Are Unaffected by Long-Term Hormone Replacement

2014 ◽  
Vol 100 (4) ◽  
pp. 334-346 ◽  
Author(s):  
Michelle M. Naugle ◽  
Andrea C. Gore
Keyword(s):  
Rhesus Monkeys ◽  
Hormone Replacement ◽  
Female Rhesus ◽  
Gnrh Neurons

scholarly journals Mammary Nodular Hyperplasia in Intact Rhesus Monkeys

1973 ◽  
Vol 10 (2) ◽  
pp. 130-134 ◽  
Author(s):  
L. W. Nelson ◽  
L. D. Shott
Keyword(s):  
Focal Nodular Hyperplasia ◽  
Rhesus Monkeys ◽  
Clinical Change ◽  
Control Female ◽  
Subcutaneous Nodules ◽  
Female Rhesus ◽  
Nodular Hyperplasia ◽  
Well Differentiated

Two control female Rhesus monkeys in long-term toxicity studies had multiple, palpable nodules in the breast regions. These subcutaneous nodules were 2–7 mm in diameter, firm, and freely movable. No progressive clinical change was observed during a follow-up of 17 or 20 months. Microscopically, one excised nodule consisted of proliferated acinar epithelial cells arranged in lobular patterns. The cells were well differentiated and presented no features of neoplasia. A diagnosis of focal nodular hyperplasia was compatible with the microscopie findings and the clinical follow-up of similar nodules.

Effect of long-term Centchroman treatment on plasma steroid and peptide hormones in female rhesus monkeys ()

Contraception ◽  
1985 ◽  
Vol 32 (3) ◽  
pp. 283-299 ◽  
Author(s):  
P.K. Nigam ◽  
B. Malaviya ◽  
S.R. Chowdhury ◽  
V.P. Kamboj ◽  
Harish Chandra
Keyword(s):  
Rhesus Monkeys ◽  
Peptide Hormones ◽  
Female Rhesus

Long-term effects of recombinant human growth hormone treatment on skeletal maturation and growth in female rhesus monkeys with normal pituitary function

1991 ◽  
Vol 130 (3) ◽  
pp. 435-441 ◽  
Author(s):  
M. E. Wilson ◽  
J. M. Tanner
Keyword(s):  
Growth Hormone ◽  
Rhesus Monkeys ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Term Treatment ◽  
Crown Rump Length ◽  
Long Term Treatment ◽  
Female Rhesus ◽  
Tibia Length

ABSTRACT Female rhesus monkeys (n = 5), having normal pituitary function, were treated for 50 months with recombinant human growth hormone (rhGH; 250 μg/kg) 3 days/week (Monday, Wednesday and Friday) and rates of growth were compared with a group of age-matched untreated females (n = 6). Treatment was initiated at 20 months of age, approximately 10 months before the expected age of menarche. Long-term treatment with rhGH accelerated bone maturation and increased the velocity of increase in crown–rump length, tibia length and body weight. The period of acceleration occurred coincident with the occurrence of spontaneous puberty. Body measurements remained larger in the treated females until growth ceased. Long-term rhGH treatment increased final adult crown–rump length by some 3%, with a slight increase in tibia length and body weight, without having any untoward effects on reproductive capacity or health. One treated animal exhibited higher estimates of antibodies to rhGH throughout the study period, and this female also had a smaller increment in crown–rump length than the other treated females. These data suggest that long-term treatment of normal-pituitary females with rhGH augments crown–rump growth without any untoward effects of health. Journal of Endocrinology (1991) 130, 435–441

The effect of long-term feeding of Aroclor 1254 to female Rhesus monkeys on their polychlorinated biphenyl tissue levels

1989 ◽  
Vol 18 (6) ◽  
pp. 858-865 ◽  
Author(s):  
Jos Mes ◽  
Douglas L. Arnold ◽  
Fred Bryce ◽  
David J. Davies ◽  
Kazimierz Karpinski
Keyword(s):  
Rhesus Monkeys ◽  
Polychlorinated Biphenyl ◽  
Aroclor 1254 ◽  
Tissue Levels ◽  
Female Rhesus

scholarly journals Complete Androgen Insensitivity Syndrome: From Bench to Bed

2021 ◽  
Vol 22 (3) ◽  
pp. 1264
Author(s):  
Nina Tyutyusheva ◽  
Ilaria Mancini ◽  
Giampiero Igli Baroncelli ◽  
Sofia D’Elios ◽  
Diego Peroni ◽  
...  
Keyword(s):  
Receptor Gene ◽  
Hormone Replacement ◽  
Basic Research ◽  
Well Being ◽  
Androgen Receptor Gene ◽  
Androgen Insensitivity Syndrome ◽  
Primary Amenorrhea ◽  
Complete Androgen Insensitivity Syndrome ◽  
Androgen Insensitivity

Complete androgen insensitivity syndrome (CAIS) is due to complete resistance to the action of androgens, determining a female phenotype in persons with a 46,XY karyotype and functioning testes. CAIS is caused by inactivating mutations in the androgen receptor gene (AR). It is organized in eight exons located on the X chromosome. Hundreds of genetic variants in the AR gene have been reported in CAIS. They are distributed throughout the gene with a preponderance located in the ligand-binding domain. CAIS mainly presents as primary amenorrhea in an adolescent female or as a bilateral inguinal/labial hernia containing testes in prepubertal children. Some issues regarding the management of females with CAIS remain poorly standardized (such as the follow-up of intact testes, the timing of gonadal removal and optimal hormone replacement therapy). Basic research will lead to the consideration of new issues to improve long-term well-being (such as bone health, immune and metabolic aspects and cardiovascular risk). An expert multidisciplinary approach is mandatory to increase the long-term quality of life of women with CAIS.

The Relationship Between Brain Fog and Medication Adherence for Individuals With Hypothyroidism

2021 ◽  
pp. 105477382110381
Author(s):  
Kelly Haskard-Zolnierek ◽  
Courtney Wilson ◽  
Julia Pruin ◽  
Rebecca Deason ◽  
Krista Howard
Keyword(s):  
Memory Impairment ◽  
Hormone Replacement ◽  
Long Term Memory ◽  
Adherence Level ◽  
Thyroid Hormone Replacement ◽  
Memory Impairments ◽  
Cognitive Failures ◽  
Short And Long Term ◽  
The Relationship

Individuals with hypothyroidism suffer from symptoms including impairments to cognition (i.e., “brain fog”). Medication can help reduce symptoms of hypothyroidism; however, brain fog may hinder adherence. The aim of this study was to determine if memory impairment and cognitive failures are related to treatment nonadherence in 441 individuals with hypothyroidism. Participants with a diagnosis of hypothyroidism and currently prescribed a thyroid hormone replacement medication were placed in two groups according to adherence level and compared on validated scales assessing impairments to memory and cognition. Results indicated a significant association between treatment nonadherence and self-reported brain fog, represented by greater cognitive and memory impairments. Nonadherent individuals indicated impairments with prospective, retrospective, and short- and long-term memory; and more cognitive failures, compared to adherent individuals. Findings suggest the importance of interventions to enhance adherence for individuals with brain fog, such as encouraging the use of reminders.

Sign in / Sign up

Export Citation Format

Share Document